louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02617576: Flavoring Oral Contrast for MR Enterography
Official title: Flavoring Oral Contrast for MR Enterography
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Taste, Altered
Lead sponsor: University of Minnesota
Sponsor class: OTHER
First posted: 2015-12-01
Enrollment: 0
Sex: ALL
Minimum age (years): 8
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pediatric patients undergoing MR enterography examinations

Brief summary: To determine if patient satisfaction, participation, and image quality improves with flavored oral contrast for MR enterography.

Detailed description: Volumen is an oral contrast agent used in MR imaging of the bowel. It has an unpleasant taste which makes it difficult for pediatric patients, especially sick pediatric patients, to drink. There are other contrast materials used in the department that are flavored to improved patient participation. The investigators hope to determine a way to flavor Volumen to improve patient participation. In doing so, the investigators hope to also improve patient satisfaction as well as imaging quality.

Eligibility criteria: Inclusion Criteria:

* pediatric patients having a MR enterography

Exclusion Criteria:

* sedated patients

Primary outcomes:
measure: the number of patients that prefer flavored contrast
timeFrame: one year
measure: bowel diameter measurements on MR Enterography
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of Minnesota
name: Kelly Dietz, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04767776: Non Inferiority Study of a Reduced Dose of Activated Charcoal on Rivaroxaban Pharmacokinetics.
Official title: Non Inferiority Study of a Reduced Dose of Activated Charcoal on Rivaroxaban Pharmacokinetics.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: Rivaroxaban,
Activated charcoal
Pharmacokinetics
Poisoning
Lead sponsor: Centre Hospitalier Universitaire de Saint Etienne
Sponsor class: OTHER
First posted: 2021-02-23
Enrollment: 12
Sex: MALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: OTHER

Brief summary: Rivaroxaban is a direct oral anticoagulant that target specifically activated factor X. Bleeding events related to rivaroxaban are the consequence of physiopathologic, pharmacokinetic issues or poisoning. A recent study, in healthy subjects, shows that activated charcoal can reduce significantly exposition to rivaroxaban. However, no results are available on the minimal dose of activated charcoal necessary in rivaroxaban poisoning. The objective of this study is to evaluate the effect of 4 dosing regimen activated charcoal on rivaroxaban pharmacokinetics. It corresponds to a randomised open trial with an incomplete cross over design (3 occasions). It will enrol 12 healthy subjects. Four treatments modalities will be studied: rivaroxaban with 50g, 24g, 12g and 6g of activated charcoal administrated 3 hours after rivaroxaban intake.


Eligibility criteria: Inclusion Criteria:

* Affiliated or beneficiary of a social security category
* Having signed the inform consent form
* Having signed the biologic consent form
* Men aged between 18 and 40 years
* Weight between 55 and 92 kilogram
* normal clinical exam
* normal biological exam

Exclusion Criteria:

* Contra-indication to rivaroxaban
* Contra-indication to activated charcoal
* With a history of hemorrhagic disease
* Smoker
* Organic lesion likely to bleed
* Severe liver disease
* Severe kidney failure
* Gastroduodenal ulcers
* Any medication taken during the week prior to the start of the study
* Consumption of grapefruit juice
* Routine ingestion of excessive amounts of coffee, tea, chocolate and/or caffeinated beverages
* Practice of violent sports
* Fructose intolerance
* Glucose-galactose malabsorption syndrome or sucrase-isomaltase deficiency syndrome
* Notable medical history (cardiovascular pathology, pulmonary, neurology ...)

Primary outcomes:
measure: plasma concentrations of rivaroxaban
timeFrame: 1, 2, 2.5, 3, 3.5, 4, 5, 7, 9, 12, 24 hours after rivaroxaban administration
Secondary outcomes:
measure: Adverse events
timeFrame: 24 hour after rivaroxaban administration
Other outcomes:
Locations:
city: Saint-etienne
country: France
facility: CHU de SAINT-ETIENNE
Study officials:
affiliation: CHU de SAINT-ETIENNE
name: Patrick MISMETTI, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02429076: EEG Studies of IV Methylphenidate-Induced Emergence From Anesthesia
Official title: Electroencephalogram Studies of Intravenous Methylphenidate-Induced Emergence From General Anesthesia
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
PHASE2
Conditions: Active Emergence From General Anesthesia
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
First posted: 2015-04-29
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 36
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The aim of this study is to test the hypothesis that methylphenidate actively induces emergence from propofol and sevoflurane general anesthesia in healthy volunteers.

Detailed description: Basic science and clinical data suggest that activation of one or more of the brain's arousal pathways is a highly plausible way to induce active emergence from general anesthesia. The investigators have compelling experimental data demonstrating that methylphenidate is highly effective in actively inducing emergence from isoflurane and propofol general anesthesia in rodents. The available literature suggests that IV methylphenidate would be safe to administer to patients recovering from general anesthesia, and that in addition to promoting arousal, it would enhance breathing. Both of these effects would be highly desirable in patients recovering from general anesthesia.

Eligibility criteria: Inclusion Criteria:

1. Age 18-36 years
2. ASA classification 1 or 2
3. Normal body weight, BMI ≤ 30
4. Non-smoker
5. Right handed
6. No history of taking stimulants

Exclusion Criteria:

* In general, patients will be excluded from the study if the state of their chronic health problems gives them an ASA physical status classification of 3 or beyond.

Primary outcomes:
measure: Response to methlyphenidate administration
timeFrame: minutes to response, expected average is less than 10 minutes
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06864676: Assessment of the Diagnostic Performance of the Detection System and Establishment of an Intelligent and Rapid Triage Model
Official title: Assessment of the Diagnostic Performance of the Detection System and Establishment of an Intelligent and Rapid Triage Model
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Coronary Heart Disease (CHD)
Keywords: ACS
Lead sponsor: China National Center for Cardiovascular Diseases
Sponsor class: OTHER_GOV
Collaborators: name: Chinese Academy of Medical Sciences, Fuwai Hospital
First posted: 2025-03-07
Enrollment: 2000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Chinese population aged 18 years and above, regardless of gender, with symptoms of chest tightness and chest pain, who need to be confirmed as acute coronary syndrome patients.

Brief summary: The rapid triage of patients with acute chest pain remains an important issue in clinical practice. This study will establish a cohort of patients suspected of acute coronary syndrome (ACS) to construct a multi-marker dynamic combined intelligent triage model. This model will triage the risk of NSTEMI in patients with chest pain at their first visit. It will also stratify the risk of patients with chest pain using major adverse cardiovascular events (MACE) within 30 days as the endpoint.


Eligibility criteria: Inclusion Criteria:

* Adults aged 18 years or above from China, regardless of gender;
* Presence of symptoms such as chest tightness and chest pain, with the need to determine whether they are patients with acute coronary syndrome;
* Ability to obtain informed consent.

Exclusion Criteria:

* - Patients with STEMI at the time of presentation;
* Patients with a clear diagnosis after tests such as troponin;
* Patients who have undergone major surgery or trauma within the past four weeks;
* Pregnant women or patients with tumors undergoing radiotherapy or chemotherapy;
* Patients who have previously participated in this study.

Primary outcomes:
measure: Myocardial infarction
timeFrame: 30 days to 6 months
Secondary outcomes:
Other outcomes:
measure: High-sensitivity troponin
timeFrame: Concentrated detection once every three months
Locations:
Study officials:
References:
Clinical trial NCT02331576: Analgesic Effect of Perineural Fentanyl Additive to Local Anesthetics in Femoral Nerve Block
Official title: Femoral Nerve Block in Patient With Total Knee Arthroplasty; Analgesic Effect of Perineural Fentanyl Additive to Local Anesthetics
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Postoperative Pain
Lead sponsor: Chonnam National University Hospital
Sponsor class: OTHER
First posted: 2015-01-06
Enrollment: 100
Sex: ALL
Minimum age (years): 60
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the analgesic efficacy of perineural fentanyl combined with local anesthetics in the post operative pain control with continuous femoral nerve block after total knee arthroplasty.


Eligibility criteria: Inclusion Criteria:

* patients who scheduled to receive knee arthroplasty with general anesthesia
* ASA physical status 1 or 2

Exclusion Criteria:

* allergy to drug
* refuse to the study
* ASA physical status 3 and 4
* history of drug abuse
* cognitive disfunction such as dementia
* patients who do not adequate for general anesthesia

Primary outcomes:
measure: Change from baseline in Visual Analogue Scales by time sequence
timeFrame: baseline(just after operation), 15, 30, 60 minute and 24 hour after intervention
Secondary outcomes:
Other outcomes:
Locations:
city: Hwasun
country: Korea, Republic of
facility: Chonnam National University Hwasun Hospital
state: Jeollanam-do
Study officials:
affiliation: assistant professor
name: Bongha Heo, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06056076: Comparison of Mini Squat and Endurance Training in Improving Quality of Life in Knee Osteoarthritis
Official title: Comparison of Mini Squat and Endurance Training in Improving Quality of Life in Knee Osteoarthritis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Knee Osteoarthritis
Lead sponsor: Neuro Counsel Hospital, Pakistan
Sponsor class: OTHER
First posted: 2023-09-28
Enrollment: 30
Sex: ALL
Minimum age (years): 40
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Single blind Randomized control trial
Primary purpose: TREATMENT

Brief summary: Interventional type of study in which one group of participants will be given mini squats training and other endurance training to improve the quality of life of knee osteoarthritis patients.

Detailed description: Interventional type of study in which one group of participants will be given mini squats training and other endurance training to improve the quality of life of knee osteoarthritis patients. 3 sessions per week for 4 weeks along with interferential therapy

Eligibility criteria: Inclusion Criteria:

* Both gender
* grade 2-3 OA
* No Comorbidity of serious type

Exclusion Criteria:

* Pain greater than 8 on PNS
* DM
* HTN
* Neurological conditions

Primary outcomes:
measure: PNS
timeFrame: 4 weeks
measure: SF-36 Quality of Life
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Islamabad
country: Pakistan
facility: Muhammad Salman, Pt
state: Federal
Study officials:
References:
Clinical trial NCT01851876: Endometrial Injury and Single Embryo Transfer
Official title: Endometrial Injury May Increase the Clinical Pregnancy Rate in Normoresponders Underwent Long Agonist Protocol Intracytoplasmic Sperm Injection Cycles With Single Embryo Transfer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Primary Infertility
Lead sponsor: Karadeniz Technical University
Sponsor class: OTHER
First posted: 2013-05-13
Enrollment: 118
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Endometrial injury increases clinical pregnancy rate in normoresponder patients undergoing long agonist protocol intracytoplasmic sperm injection cycles with single embryo transfer.

Detailed description: Endometrial injury means endometrial biopsy on day 3 of menstrual cycle following down regulation in an IVF patient.

Eligibility criteria: Inclusion Criteria:

* woman age under 35 years
* history of primary infertility
* normoresponder (antral follicle count 5-10 in one ovary in early follicular phase
* having grade I or II embryos for transfer
* agree to undergo endometrial biopsy during the COH cycle. All patients were stimulated with luteal phase long protocol.

Exclusion Criteria:

* endocrinopathies (including diabetes mellitus, hyperprolactinemia, Cushing's disease, and congenital adrenal hyperplasia), any systemic disease, collagen disorder, hypercholesterolemia, sickle cell anemia, and a history of neoplasm; -high risk for or history of OHSS
* using any concurrent medication (e.g., insulin-sensitizing drugs, and GnRH antagonists)
* patients who did not proceed to follicle retrieval
* severe male infertility requiring TESA/TESA
* mullerian tract anomalies
* a history of endometrial instrumentation or surgery within a month of the study
* not agree to undergo endometrial biopsy during the COH cycle.

Primary outcomes:
measure: Clinical Pregnancy Rate
timeFrame: up to 6 months
measure: Clinical Pregnancy Rate
timeFrame: 4 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Karadeniz Technical University
name: Suleyman Guven
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02934776: Prospective Cohort Study of the Ability of MRI/DTI to Diagnose Prostate Cancer
Official title: Prospective Cohort Study of the Ability of MRI/DTI to Diagnose Prostate Cancer in Men Undergoing Prostate MRI
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Magnetic Resonance Imaging
Keywords: DTI
prostate cancer
MRI
Lead sponsor: Rabin Medical Center
Sponsor class: OTHER
Collaborators: name: Weizmann Institute of Science
First posted: 2016-10-17
Enrollment: 200
Sex: MALE
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to examine if investigators can improve diagnosis of prostate cancer by using MRI/DTI?

Detailed description: This is a prospective cohort study of the ability of MRI/DTI to diagnose prostate cancer in men undergoing prostate MRI.

Study design: Male adults who are scheduled to undergo MRI of the prostate, for clinical reasons, will be subjected to additional 10 minutes of image acquisition inside the MRI machine. The added MRI/DTI acquisition does not involve injection of additional contrast material. Investigators will compare between ability of the full mp-MRI images to diagnose prostate cancer to that of the MRI/DTI images

Eligibility criteria: Inclusion Criteria:

1. Men who are scheduled to undergo MRI of the prostate at the Department of Imaging, in Beilinson Hospital, Rabin Medical Center
2. Age 18-90.
3. Men who are willing and able to sign an informed consent form.

Exclusion Criteria:

1) Men who cannot complete the full acquisition of the MRI and the MRI/DTI image sequences for any reason.

Primary outcomes:
measure: Compare between number of prostate cancer diagnosed by mpMRI to the ones diagnosed by MRI/DTI
timeFrame: 1 year
Secondary outcomes:
measure: Compare the correlation of MRI/DTI parameters with prostate cancer diagnosis to the ones measured by mpMRI (ADC, and diffusion weighted images).
timeFrame: 1 year
measure: Compare between MRI/DTI and MRI ability to identify low-grade and high-grade prostate cancer
timeFrame: 1 year
measure: Compare between MRI/DTI and MRI in their ability to estimate tumor size.
timeFrame: 1 year
measure: Compare between MRI/DTI and MRI in PiRAD grading
timeFrame: 1 year
Other outcomes:
Locations:
city: Petah-Tikva
country: Israel
facility: Rabin Medical Center
Study officials:
References:
Clinical trial NCT00225576: Statewide Implementation of Electronic Health Records
Official title: Statewide Implementation of Electronic Health Records
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Medication Errors
Keywords: medication errors
adverse drug events
electronic health records
Lead sponsor: Agency for Healthcare Research and Quality (AHRQ)
Sponsor class: FED
Collaborators: name: Massachusetts eHealth Collaborative
First posted: 2005-09-26
Enrollment: 2030
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: PREVENTION

Brief summary: To determine the effects of Electronic Health Record use on medication error rates in primary care office practices.

Hypothesis: Adoption of Electronic Health Records through this program will reduce medication errors

Detailed description: From the practices committed to implementing EHR in early 2005, we randomly selected 15 adult community-based primary care physicians. We selected 15 similar physicians in practices that were not planning to adopt in that time period.

At each of these physicians' practices we documented rates of medication errors for one week prior to the implementation of an EHR using duplicate prescription pads. Two months after the implementation in the adopting group, allowing some time for familiarization with the tool, we collected two weeks of data using computer-based information (in the adopting arm) and duplicate prescriptions (in the non-adopting arm).

Eligibility criteria: Inclusion Criteria:

* All patients of physicians participating in the study

Exclusion Criteria:

* Any patients who are not part of a panel of a participating physician
* Any patients who are younger than 18 years of age
* Any patients who came in for a second visit within each data collection period

Primary outcomes:
measure: 1. Medication errors
timeFrame: 2005-2007
measure: 2. Near misses
timeFrame: 2005-2007
measure: 3. Adverse drug events
timeFrame: 2005-2007
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Brigham and Women's Hospital
state: Massachusetts
Study officials:
affiliation: Brigham and Women's Hospital, Partners Healthcare System Inc.
name: David W. Bates, MD, MPH
role: PRINCIPAL_INVESTIGATOR
affiliation: Cornell Weill Medical College
name: Rainu Kaushal, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
citation: Abramson EL, Bates DW, Jenter C, Volk LA, Barron Y, Quaresimo J, Seger AC, Burdick E, Simon S, Kaushal R. Ambulatory prescribing errors among community-based providers in two states. J Am Med Inform Assoc. 2012 Jul-Aug;19(4):644-8. doi: 10.1136/amiajnl-2011-000345. Epub 2011 Dec 1.
Clinical trial NCT05825976: Omega-3 Fatty Acid Supplementation and Tear Film Quality in Celiac Patients
Official title: The Influence of Omega-3 Fatty Acid Supplementation on The Tear Film Quality in Celiac Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Dry Eye Syndromes
Celiac Disease
Keywords: Celiac Disease
Supplementation
Omega-3 Fatty Acids
Dry Eye Syndromes
Lead sponsor: Josip Juraj Strossmayer University of Osijek
Sponsor class: OTHER
Collaborators: name: Plava Medical Group, Bosna and Herzegovina
First posted: 2023-04-24
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study aims to determine the effectiveness on the tear film quality and symptoms related with dry eye disease in patients with celiac disease.

Detailed description: Patients diagnosed with celiac disease will be recruited for the study. They will be randomly assigned to one of the three arms (Intervention group 1 - high dose EPA and DHA, Intervention group 2 - low dose EPA and DHA, or Control - extra virgin olive oil) and for 45 days take supplementation as instructed. During the intervention they will be instructed to maintain their diet and lifestyle (i.e. they will not receive any education on diet or lifestyle modification). At inclusion, patients will complete one basic questionnaire on sociodemographic data, one questionnaire which assess accidental exposure to gluten and their weight and height will be measured. Subjective symptoms related to dry eye disease will be assessed with Ocular Surface Disease Index (OSDI) test, while quality and quantity of the tear film will be assessed with the Schirmer's test I and Tear Break-up Time test (TBUT). Dietary intake of omega-3 acids will be controlled by one 24-hour dietary recall (completed at inclusion an after the intervention).

Eligibility criteria: Inclusion Criteria:

* diagnosis of celiac disease
* signed informed consent form

Exclusion Criteria:

* use of medications for diabetes, hypertension, depression, thyroid disease, allergies, epilepsy, psychosis, glaucoma
* use of oral contraceptive pills
* alcoholism or use of alcohol on the day of recruitment
* menopause
* eye trauma or surgery in the past 3 months
* wearing contact lens
* supplementation with omega-3 fatty acids regardless of the dose used in the past month
* not understanding Bosnian letter or language
* Informed consent form not signed

Primary outcomes:
measure: Subjective symptoms of Dry Eye
timeFrame: 45 days
measure: Tear Break-up Time
timeFrame: 45 days
measure: Schirmer tear test
timeFrame: 45 days
Secondary outcomes:
Other outcomes:
Locations:
city: Tuzla
country: Bosnia and Herzegovina
facility: Plava Medical Group
Study officials:
affiliation: Josip Juraj Strossmayer University of Osijek, Faculty of Food Technology, Department of Food and Nutrition Research
name: Ines Banjari, PhD
role: PRINCIPAL_INVESTIGATOR
References: